USPTO serial 88985441
RENMAB
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 18, 2025
- Examiner
- CROWLEY, SEAN MICHAEL
- Law office
- INTENT TO USE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with RENMAB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
Daxing District, Beijing, CN
Other trademarks owned by BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
Daxing District, Beijing, CN
Other trademarks owned by BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
Beijing, CN
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
BEIJING, CN
Other trademarks owned by BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
CYNTHIA JOHNSON WALDEN
CYNTHIA JOHNSON WALDEN Fish & Richardson P.C.PO BOX 1022MINNEAPOLIS, MN 55440-1022United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | (Based on 44(e)) Chemical additives for insecticides; nitrogen fertilizer; food preservative chemicals; biological preparations not for medical or veterinary use; radioactive elements for scientific purposes; diagnostic preparations not for medical or veterinary use; protein in raw material form for scientific and medical research, and industrial use; plasticizers being industrial chemicals; industrial adhesives; industrial chemicals, not for medical use | ACTIVE | — |
| 031 | (Based on 44(e)) Live experimental animal; live animals; live poultry; live hamster; live swine; living trees; plant seeds; hay; living plants | ACTIVE | — |
| 042 | (Based on 44(e)) Drug development services for others provided via a platform for antibody discovery that features experimental animal research; drug evaluations being pharmaceutical research provided via a platform for antibody discovery that features experimental animal research; pharmaceutical research provided via a platform for antibody discovery that features experimental animal research; Implementation of early assessment in new drug development fields for others, involving experimental animals, to support the development by others of pharmaceutical preparations and medicines; development of pharmaceutical preparations and medicines provided via a platform for antibody discovery that features experimental animal research; clinical trials being pharmaceutical and scientific research services provided via a platform for antibody discovery that features experimental animal research; package design; research and development of antibodies provided via a platform for antibody discovery that features experimental animal research; research and development of new products for others provided via a platform for antibody discovery that features experimental animal research; products development for others provided via a platform for antibody discovery that features experimental animal research; consulting services in biotechnology development fields involving experimental animal research and antibodies discovered from the same, the aforementioned also provided via a platform for antibody discovery that features experimental animal research; biological research and analyses provided via a platform for antibody discovery that features experimental animal research; biochemistry research and analyses provided via a platform for antibody discovery that features experimental animal research; biotechnology research provided via a platform for antibody discovery that features experimental animal research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
- Other trademarks owned by BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
- Other trademarks owned by Beijing Biocytogen Co., Ltd.
- Other trademarks owned by BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
- Other trademarks in Class 001
- Other trademarks in Class 031
- Other trademarks in Class 042
- Similar marks named RENMAB
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 18, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 18, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 27, 2025 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Oct 27, 2025 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Oct 27, 2025 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Oct 23, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 2, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 1, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 1, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 19, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 18, 2025 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| May 18, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 18, 2025 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| May 13, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 1, 2025 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Nov 19, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 21, 2024 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Oct 21, 2024 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Oct 21, 2024 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Feb 14, 2022 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Sep 15, 2021 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Aug 17, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 17, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 28, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 9, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 9, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 9, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 6, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Feb 17, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jan 5, 2021 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jan 5, 2021 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jan 5, 2021 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Dec 2, 2020 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 29, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 29, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 29, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 12, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 12, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 8, 2020 | ALIE | ASSIGNED TO LIE | — |
| May 5, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 5, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 5, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 5, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 28, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 14, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 3, 2019 | NWAP | NEW APPLICATION ENTERED | — |